BRPI0607109A2 - formulações de gel aquoso contendo 1-(2-metilpropil)-1h-imidazo-[4,5-c][1,5]naftiridin-4-amin a e kit - Google Patents

formulações de gel aquoso contendo 1-(2-metilpropil)-1h-imidazo-[4,5-c][1,5]naftiridin-4-amin a e kit

Info

Publication number
BRPI0607109A2
BRPI0607109A2 BRPI0607109-0A BRPI0607109A BRPI0607109A2 BR PI0607109 A2 BRPI0607109 A2 BR PI0607109A2 BR PI0607109 A BRPI0607109 A BR PI0607109A BR PI0607109 A2 BRPI0607109 A2 BR PI0607109A2
Authority
BR
Brazil
Prior art keywords
imidazo
amine
naphthyridin
methylpropyl
kit
Prior art date
Application number
BRPI0607109-0A
Other languages
English (en)
Inventor
David Q Ma
Christopher S Perman
Raymond D Skwierczynski
John C Hedenstrom
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of BRPI0607109A2 publication Critical patent/BRPI0607109A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)

Abstract

FORMULAçõES DE GEL AQUOSO CONTENDO 1-(2-METILPROPIL)-1 H-IMIDAZO-[4,5-C][1 ,5]NAFTIRIDIN-4-AMINA E KIT. A presente invenção refere-se a formulações farmacêuticas em uma formulação de gel aquoso incluindo 1 -(2-metilpropil)-1 H-imidazo[4,5-c][1 ,5]naftiridin-4-amina. Também são providos métodos de uso e kits.
BRPI0607109-0A 2005-02-04 2006-02-03 formulações de gel aquoso contendo 1-(2-metilpropil)-1h-imidazo-[4,5-c][1,5]naftiridin-4-amin a e kit BRPI0607109A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64993205P 2005-02-04 2005-02-04
US69841605P 2005-07-12 2005-07-12
PCT/US2006/003745 WO2006084073A2 (en) 2005-02-04 2006-02-03 Aqueous gel formulations containing 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine

Publications (1)

Publication Number Publication Date
BRPI0607109A2 true BRPI0607109A2 (pt) 2009-08-04

Family

ID=36777933

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607109-0A BRPI0607109A2 (pt) 2005-02-04 2006-02-03 formulações de gel aquoso contendo 1-(2-metilpropil)-1h-imidazo-[4,5-c][1,5]naftiridin-4-amin a e kit

Country Status (14)

Country Link
US (1) US20080207675A1 (pt)
EP (1) EP1845980A2 (pt)
JP (1) JP2008530014A (pt)
KR (1) KR20070102728A (pt)
AR (1) AR053807A1 (pt)
AU (1) AU2006210587A1 (pt)
BR (1) BRPI0607109A2 (pt)
CA (1) CA2596358A1 (pt)
IL (1) IL184825A0 (pt)
MX (1) MX2007009448A (pt)
NO (1) NO20074490L (pt)
RU (1) RU2007129248A (pt)
TW (1) TW200638931A (pt)
WO (1) WO2006084073A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006017920A2 (en) 2004-08-18 2006-02-23 Alellyx S.A. Polynucleotides, dna constructs and methods for the alteration of plant lignin content and/or composition
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
CA2597092A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245776B1 (en) * 1999-01-08 2001-06-12 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
DE60228611D1 (de) * 2001-11-29 2008-10-09 3M Innovative Properties Co Pharmazeutische formulierung umfassend ein die immunantwort modifizierendes mittel

Also Published As

Publication number Publication date
US20080207675A1 (en) 2008-08-28
NO20074490L (no) 2007-10-30
IL184825A0 (en) 2007-12-03
EP1845980A2 (en) 2007-10-24
AR053807A1 (es) 2007-05-23
WO2006084073A3 (en) 2007-06-28
KR20070102728A (ko) 2007-10-19
TW200638931A (en) 2006-11-16
RU2007129248A (ru) 2009-03-10
MX2007009448A (es) 2008-03-10
WO2006084073A2 (en) 2006-08-10
CA2596358A1 (en) 2006-08-10
JP2008530014A (ja) 2008-08-07
AU2006210587A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
AR048175A1 (es) Compuesto pirazolo (3,4-b) piridina y su uso como inhibidor pde4
CY1109722T1 (el) Ενδιαμεσες ενωσεις για την παρασκευη της trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,73oxepino[4,5-c]pyrrole
BRPI0519302A2 (pt) etanossulfonato de sais de 1-(2-metilpropil)-1h-imidazo[4,5-c][1,5]naftiridin-4-amin o e metanossulfonato de 1-(2-metilpropil)-1h-imidazo[4,5-c][1,5]naftiridin-4-amin a, composiÇÕes contendo os mesmos, processos de preparaÇço e uso
CL2007002095A1 (es) Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composicion empacada; metodo para esterilizarla; util para cicatrizar tejido donde la dermis se ha desgarrado.
NO20076651L (no) Fremgangsmate for fremstilling av 2-metyl-l-(2-metylpropyl)-1H-imidazo[4,5-c] [1,5]naftyridin-4-amin
BRPI0921798A2 (pt) azepino[4,5-b]indóis e métodos de uso
CR20160475A (es) Derivados de ácido 1-amino-2-ciclobutiletilborónico
DE60317529D1 (de) Imidazopyridine als hemmstoffe cyclin abhängiger kinasen
SV2008002972A (es) Composiciones, metodos y usos de anticuerpos humanos anti-il-23 ref. cen5117sv
BRPI0720124A2 (pt) Composições farmacêuticas e seus métodos de uso.
ZA200800144B (en) Human placental collagen compositions, processes for their preparation, methods of their use and kits comprising the compositions
CL2008002082A1 (es) Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades.
WO2004074434A3 (en) Methods and compositions for administering therapeutic and diagnostic agents
NO20081618L (no) Anvendelse av proteiner som en antiskumdannende komponent i drivstoff
ECSP088363A (es) Gel de testosterona y metodo de uso
UY28855A1 (es) Derivados de la 1-amino-ftalazina su preparación y su uso en terapia
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
CL2004001678A1 (es) Compuestos derivados de oxazolidinona; composicion farmaceutica; y uso de los compuestos como agentes bacterianos.
CO6420349A2 (es) Novedoso derivados de compuestos esteroidal[3,2-c]pirazoles con actividad glucocorticoide
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
CY1112121T1 (el) ΠΑΡΑΓΩΓΑ ΤΩΝ 1,2,3,4-ΤΕΤΡΑΫΔΡΟΠΥΡΡΟΛΟ-[1,2-α]-ΠΥΡΑΖΙΝ-6-ΚΑΡΒΟΞΑΜΙΔΙΩΝ ΚΑΙ ΤΩΝ 2,3,4,5-ΤΕΤΡΑΫΔΡΟΠΥΡΡΟΛΟ-(1,2-α)-ΔΙΑΖΕΠΙΝ-7-ΚΑΡΒΟΞΑΜΙΔΙΩΝ, Η ΠΑΡΑΣΚΕΥΗ ΤΟΥΣ ΚΑΙ Η ΕΦΑΡΜΟΓΗ ΤΟΥΣ ΣΕ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ
ITMI20040678A1 (it) Uso di composti per il trattamento antibiotico sostitutivo preferibilmente ma non esclusivamente in zootecnia
UY31587A1 (es) Derivados de n-heterociclico-imidazo[1,2-a]piridina-2-carboxamidas, su preparacion y su aplicacion en terapéutica.
UY29046A1 (es) Derivados de n-(1h-indolil)-1h-indol-2-carboxamidas, su preparación y su uso en terapia
BRPI0607109A2 (pt) formulações de gel aquoso contendo 1-(2-metilpropil)-1h-imidazo-[4,5-c][1,5]naftiridin-4-amin a e kit

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.